Scandion Oncology has announced that the first patient in part 3 of the Phase II CORIST trial has been dosed. The CORIST development programme is investigating the use of the company’s chemotherapy ...
Scandion Oncology, an innovative drug efflux pump inhibition company using biomodulation capability to revert drug resistance, announces final data from CORIST trial part 1, 2 and 3. In this phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results